Penetration of voriconazole, 1%, eyedrops into human aqueous humor: A prospective open-label study

Abstract

Objective: To determine the therapeutic efficacy of adjuvant use of voriconazole, 1%, eyedrops in the treatment of refractory fungal keratitis. Methods: A prospective open-label trial was conducted to determine voriconazole levels obtained in human aqueous humor after administration of a 1% solution, preserved with 0.01% benzalkonium chloride, every 6 hours for 3 days, or hourly for 4 doses. Ten participants were selected among patients scheduled to undergo elective anterior segment surgery, and samples were tested using validated high-performance liquid chromatography. Results: The mean (SD) voriconazole concentrations after hourly dosing (n=5) was 1.90 (1.12) μg/mL and after a single dosin..